Literature DB >> 32406078

COVID-19 in an elderly patient treated with secukinumab.

Vito Di Lernia1, Caterina Bombonato1, Alberico Motolese1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32406078     DOI： 10.1111/dth.13580

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN： 1396-0296            Impact factor:   2.851


× No keyword cloud information.
  12 in total

Review 1.  What Has Changed in the Treatment of Psoriatic Arthritis After COVID-19?

Authors:  Yaşar Keskin; Gökhan Koz; Kemal Nas
Journal:  Eurasian J Med       Date:  2021-06

Review 2.  Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review.

Authors:  Ilke Coskun Benlidayi; Behice Kurtaran; Emre Tirasci; Rengin Guzel
Journal:  Rheumatol Int       Date:  2020-06-26       Impact factor: 2.631

3.  Safety of secukinumab treatment in COVID-19 affected psoriatic patients.

Authors:  Cristina Mugheddu; Silvia Sanna; Laura Atzori; Franco Rongioletti
Journal:  Dermatol Ther       Date:  2021-01-03       Impact factor: 3.858

Review 4.  The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong?

Authors:  Dounia Darif; Ikram Hammi; Ayyoub Kihel; Imane El Idrissi Saik; Fadila Guessous; Khadija Akarid
Journal:  Microb Pathog       Date:  2021-02-18       Impact factor: 3.848

Review 5.  Biologics for Psoriasis During the COVID-19 Pandemic.

Authors:  Huanhuan Zeng; Siyu Wang; Ling Chen; Zhu Shen
Journal:  Front Med (Lausanne)       Date:  2021-12-06

Review 6.  Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease.

Authors:  Alfonso Motolese; Manuela Ceccarelli; Laura Macca; Federica Li Pomi; Ylenia Ingrasciotta; Giuseppe Nunnari; Claudio Guarneri
Journal:  Biomedicines       Date:  2022-01-21

Review 7.  Patients with specific skin disorders who are affected by COVID-19: What do experiences say about management strategies? A systematic review.

Authors:  Niloufar Najar Nobari; Azadeh Goodarzi
Journal:  Dermatol Ther       Date:  2020-07-07       Impact factor: 3.858

Review 8.  Biologics for Psoriasis during the COVID-19 Pandemic.

Authors:  Koji Kamiya; Mayumi Komine; Mamitaro Ohtsuki
Journal:  J Clin Med       Date:  2021-03-30       Impact factor: 4.241

Review 9.  Recent advances in antibody-based immunotherapy strategies for COVID-19.

Authors:  Abdolreza Esmaeilzadeh; Samaneh Rostami; Pegah M Yeganeh; Safa Tahmasebi; Majid Ahmadi
Journal:  J Cell Biochem       Date:  2021-06-23       Impact factor: 4.480

10.  National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1.

Authors:  Joel M Gelfand; April W Armstrong; Stacie Bell; George L Anesi; Andrew Blauvelt; Cassandra Calabrese; Erica D Dommasch; Steve R Feldman; Dafna Gladman; Leon Kircik; Mark Lebwohl; Vincent Lo Re; George Martin; Joseph F Merola; Jose U Scher; Sergio Schwartzman; James R Treat; Abby S Van Voorhees; Christoph T Ellebrecht; Justine Fenner; Anthony Ocon; Maha N Syed; Erica J Weinstein; Jessica Smith; George Gondo; Sue Heydon; Samantha Koons; Christopher T Ritchlin
Journal:  J Am Acad Dermatol       Date:  2020-09-04       Impact factor: 15.487
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.